A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 12 Jan 2026
At a glance
- Drugs Dusquetide (Primary)
- Indications Stomatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Soligenix
Most Recent Events
- 18 Dec 2025 According to a Soligenix media release, results have been published in Rheumatology.
- 18 Dec 2025 Results presented in the Soligenix Media Release.
- 29 Aug 2018 According to a Soligenix media release, data from this trial will be presented at the 2018 ESCMID/ASM Conference.